The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Open accessAbstract
IMPORTANCE: The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective in patients with chronic lymphocytic leukemia (CLL). Reasons for discontinuing therapy with this drug and outcomes following discontinuation have not been evaluated outside of clinical trials with relatively short follow-up. OBJECTIVE: To determine features associated with discontinuation of ibrutinib therapy and outcomes. DESIGN, SETTING, AND PARTICIPANTS: A total of 308 patients participating in 4 sequential trials of ibrutinib at The Ohio State University Comprehensive Cancer Center were included. These clinical trials accrued patients included in this analysis from May 2010 until April 2014, and data were locked in June 2014. MAIN OUTCOMES AND MEASURES: Patients were evaluated for time to therapy discontinuation, reasons for discontinuation, and survival following discontinuation. For patients who discontinued therapy because of disease progression, targeted deep sequencing was performed in samples at baseline and time of relapse. RESULTS: With a median follow-up of 20 months, 232 patients remained on therapy, 31 had discontinued because of disease progression, and 45 had discontinued for other reasons. Disease progression includes Richter's transformation (RT) or progressive CLL. Richter's transformation appeared to occur early and CLL progressions later (cumulative incidence at 12 months, 4.5% [95% CI, 2.0%-7.0%] and 0.3% [95% CI, 0%-1.0%], respectively). Median survival following RT was 3.5 months (95% CI, 0.3-6.0 months) and 17.6 months (95% CI, 4.7 months-"not reached") following CLL progression. Sequencing on peripheral blood from 8 patients with RT revealed 2 with mutations in BTK, and a lymph node sample showed no mutations in BTK or PLCG2. Deep sequencing on 11 patients with CLL progression revealed BTK or PLCG2 mutations in all. These mutations were not identified before treatment in any patient. CONCLUSIONS AND RELEVANCE: This single-institution experience with ibrutinib confirms it to be an effective therapy and identifies, for the first time, baseline factors associated with ibrutinib therapy discontinuation. Outcomes data show poor prognosis after discontinuation, especially for those patients with RT. Finally, sequencing data confirm initial reports associating mutations in BTK and PLCG2 with progression and clearly show that CLL progressions are associated with these mutations, while RT is likely not. TRIAL REGISTRATIONS: clinicaltrials.gov Identifiers:NCT01105247, NCT01217749, NCT01589302, and NCT01578707.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In published studies of disease progression during BTKi therapy,approximately 35% of patients were found to have aBTK mutation alone, an additional 10% had a coexisting mutations in PLCG2, 5% of cases had a PLCG2mutation alone, and the remaining 50% were wild-type (WT) for BTK and PLCG2 (Figure 2)(12, 19, 21–31).”
From Resistance Mechanisms and Approach to Chronic Lymphocytic Leukemia after BTK Inhibitor Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Interestingly, two separate studies observed that there were no PLCγ2 or BTK mutations detected in patients with CLL before Ibrutinib treatment (127, 128).”
From The role of PLCγ2 in immunological disorders, cancer, and neurodegeneration (2021) · cites this paper as [128]
In the citing paper
“While the most common ibrutinib-resistant BTK mutant is C481S, other mutants observed in patients include C481R, C481F, C481Y, T474I, and T474S.33”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,957
Clinical staging of chronic lymphocytic leukemia
Rai, K., Sawitsky, A., Ep, C., Chanana, A. D., Levy, R., & Pasternack, B. (1975) · Blood · doi:10.1182/blood.v46.2.219.219 · Cited by 2,789
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Self-citationIdelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,725
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S. M., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S. E., Tam, C. S. L., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,665
Self-citationResistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275
Self-citationDubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., et al. (2013) · Blood · doi:10.1182/blood-2013-06-507947 · Cited by 810
Self-citationHerman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Self-citationPonader, S., Chen, S.-S., Buggy, J. J., Balakrishnan, K., Gandhi, V., Wierda, W. G., Keating, M. J., O'Brien, S., Chiorazzi, N., & Burger, J. A. (2012) · Blood · doi:10.1182/blood-2011-10-386417 · Cited by 640
Cited by
Sorted by citations
Items 501–585 of 585
Transplantation in CLL: what we can learn from a dinosaur
Dreger, P., & Montserrat, E. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.27 · Cited by 1
Likold, E. B., Вениаминовна, Б. Б., Февралева, И. С., Severina, N. A., Dmitrieva, E. A., Petrenko, A. A., Nikitin, E. A., & Sudarikov, A. B. (2023) · Гематология и трансфузиология · doi:10.35754/0234-5730-2023-68-2-182-194 · Cited by 1
Schleicher, T. K., Cohen, M., & Graf, S. A. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2465365 · Cited by 1
Brander, D. M. (2016) · British Journal of Haematology · doi:10.1111/bjh.14446 · Cited by 1
Managing BTK Inhibitor-Refractory CLL
Wierda, W. G. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.08.088 · Cited by 1
Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia
Awan, F. T., & Kharfan‐Dabaja, M. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-56802-9.00012-2 · Cited by 1
Self-citationChoi, M. Y., Wang, H., & Kipps, T. J. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.05.013 · Cited by 1
Ibrutinibrezisztencia krónikus limfocitás leukémiában
Aczél, D., Mátrai, Z., Kiss, R., Balogh, A., Illés, S., Bödör, C., & Alpár, D. (2019) · Hematológia–Transzfuziológia · doi:10.1556/2068.2019.52.2.8 · Cited by 1
New Pharmacotherapies in Chronic Lymphocytic Leukemia.
Olin, J. L., Canupp, K., & Smith, M. B. (2017) · Europe PMC (PubMed Central) · Cited by 1
Resistance to Bruton’s Tyrosine Kinase Signaling Pathway Targeted Therapies
Chu, Y., Cairo, M. S., & Beishuizen, A. (2019) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-24424-8_6 · Cited by 1
Tridente, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809400-6.00027-5 · Cited by 1
[Clinical value of PET/CT in the diagnosis of Richter syndrome].
Zheng, X. Q., Zhu, H., Ding, C., Wang, L., Fan, L., Xu, W., & Li, J. Y. (2020) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2020.08.015 · Cited by 1
Santoro, R., Falbo, M., Levato, L., Iannaccaro, P., & Prejanò, S. (2020) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000981 · Cited by 1
Koshiishi, M., Odate, T., Nakagawa, Y., Suzuki, J., Kumagai, T., Kawashima, I., Yamamoto, T., Nakajima, K., Tanaka, M., Oishi, N., et al. (2021) · Internal Medicine · doi:10.2169/internalmedicine.6979-20 · Cited by 1
Ibrutinib associated cardiovascular events in a patient wearing an implanted loop recorder
Rivera, D., Takahashi, K., Durand, J., & Ferrajoli, A. (2021) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2021.044 · Cited by 1
Çeli̇k, S., Demirağ, A. D., ARSLAN, S., Özel, A. E., & Akyüz, S. (2022) · Open Journal of Nano · doi:10.56171/ojn.1004702 · Cited by 1
Pozzi, S., Potenza, L., Giusti, D., Colaci, E., Pioli, V., Leonardi, G., Maccaferri, M., Luppi, M., & Marasca, R. (2022) · American Journal of Case Reports · doi:10.12659/ajcr.935941 · Cited by 1
Zhu, Y., Ding, H., Gou, K., Sun, B., Chen, Y., & Zhang, H. (2022) · Biomedical Chromatography · doi:10.1002/bmc.5504 · Cited by 1
Burgeoning Data on BTK Inactivating Mutations in Lymphomagenesis and Therapeutic Resistance
Risso, C. B., Tsai, D., Montoya, S., Jahn, J., & Taylor, J. (2022) · Medical Research Archives · doi:10.18103/mra.v10i10.3182 · Cited by 1
[Clonality relatedness and molecular characteristics of Richter transformation].
Sha, Y., Jiang, R., Miao, Y., Qiu, T., Qin, S., Qiu, J. Y., Mi, H., Wu, W., Qiao, C., Wu, Y., et al. (2022) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2022.10.007 · Cited by 1
Zhu, J., Zhu, X., Xie, F., Ding, Y., Lu, H., Dong, Y., Li, P., Fu, J., Liang, A., Zeng, Y., et al. (2023) · Pathology & Oncology Research · doi:10.3389/pore.2023.1611070 · Cited by 1
Chen, Q., Jain, N., Flowers, C. R., & Chhatwal, J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.2769 · Cited by 1
Klintman, J., Stamatopoulos, B., Ridout, K., Eyre, T. A., Pascua, L. L., Appleby, N., Knight, S. J. L., Dreau, H. M.-P., Popitsch, N. P., Ehinger, M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/644542 · Cited by 1
Tadmor, T., & Greenfeld, S. M. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1734596 · Cited by 1
Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia
Molica, S., Allsup, D. J., & Polliack, A. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2087072 · Cited by 1
Joseph, R. E., Wales, T. E., Jayne, S., Britton, R. G., Fulton, D. B., Engen, J. R., Dyer, M. J. S., & Andreotti, A. H. (2024) · eLife · doi:10.7554/elife.95488.1 · Cited by 1
Role of precision medicine in the treatment of chronic lymphocytic leukaemia
Bruce, D., & Schuh, A. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2016.1159510
Metaphase Cytogenetics in Chronic Lymphocytic Leukemia
Miller, C. R., Muthusamy, N., Breidenbach, H., Puski, A., Byrd, J. C., & Heerema, N. A. (2016) · Current Genetic Medicine Reports · doi:10.1007/s40142-016-0090-5
Self-citationCost-effective management of chronic diseases: surveillance, treatment, and elimination
Chen, Q. (2016) · SMARTech Repository (Georgia Institute of Technology)
Mechanistic Elements of BAFF-BCR Crosstalk in Chronic Lymphocytic Leukemia
Sreekantham, B. (2017) · doi:10.15760/honors.407
Chronische lymphatische Leukämie beim alten und geriatrischen Patienten
Goede, V., Hallek, M. J., & Eichhorst, B. F. (2018) · Springer eBooks · doi:10.1007/978-3-662-48727-3_19
Chronic Lymphocytic Leukemia in Older Adults
Goede, V., Hallek, M. J., & Eichhorst, B. F. (2017) · Springer eBooks · doi:10.1007/978-3-319-44870-1_43-1
BTK Inhibitors: Focus on Ibrutinib and Similar Agents
Mattsson, M., & Scarfò, L. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-75184-9_1
Wang, W., Zhou, X., & Li, X. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.05.34
The Eμ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia
McClanahan, F., & Gribben, J. G. (2018) · Springer eBooks · doi:10.1007/978-3-319-64597-1_139-1
Puła, B. (2018) · International Journal of Hematology and Oncology · doi:10.4999/uhod.182958
Chronic Lymphocytic Leukemia with Alterations in TP53
Coombs, C. C. (2019) · Springer eBooks · doi:10.1007/978-3-030-25610-4_4
Bruton tyrosine kinase in immunodeficiency and in B-cell malignancy
Wang, Q. (2020) · Figshare
Brown, J. R. (2020) · Blood · doi:10.1182/blood.2020005886
Karunakaran, P. (2020) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/ijmpo.ijmpo_36_20
Mantle Cell Lymphoma: Therapeutics and Management
Nabrinsky, E., & Danilov, A. V. (2020) · Molecular and translational medicine · doi:10.1007/978-3-030-49741-5_6
Development of Small Molecule Kinase Degraders as Chemical Biology Probes and Cancer Therapies
Dobrovolsky, D. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Smolewski, P., & Robak, T. (2021) · Kompass Onkologie · doi:10.1159/000516683
Acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence
Petrenko, A. A., Kislova, M. I., Dmitrieva, E. A., & Nikitin, E. A. (2021) · Journal of Modern Oncology · doi:10.26442/18151434.2021.2.200957
Approaches to Therapy of Richter Syndrome
Condoluci, A., & Rossi, D. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(21)01242-8
Lamanna, N. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(21)01203-9
Christidi, E. (2021) · cIRcle (University of British Columbia) · doi:10.14288/1.0402336
Schuh, A. (2019) · Hematologic malignancies · doi:10.1007/978-3-030-11392-6_4
The Eμ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia
McClanahan, F., & Gribben, J. G. (2019) · Springer eBooks · doi:10.1007/978-3-319-99375-1_139
Gandhi, V. V., & Bose, P. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.725994198.793538192
Condoluci, A., & Rossi, D. (2019) · Hematologic malignancies · doi:10.1007/978-3-030-11392-6_10
Chronische lymphatische Leukämie beim alten und geriatrischen Patienten
Goede, V., Hallek, M. J., & Eichhorst, B. F. (2017) · Springer eBooks · doi:10.1007/978-3-662-49083-9_19-1
Gandhi, V. V., & Bose, P. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727114985.793538170
Chronic Lymphocytic Leukemia in Older Adults
Goede, V., Hallek, M. J., & Eichhorst, B. F. (2020) · Springer eBooks · doi:10.1007/978-3-319-57415-8_43
周, 卓. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.131150
Sharifi, M., Farajzadegan, Z., & Jouzdani, S. R. (2023) · PubMed Central · doi:10.22088/cjim.14.1.1
Stephens, D. M., Huang, Y., Ruppert, A. S., Walker, J. S., Canfield, D., Cempre, C. B., Fu, Q., Baker, S. D., Hu, B., Shah, H., et al. (2023) · doi:10.1158/1078-0432.c.6532472
Self-citationWoyach, J. A., Ghia, P., Byrd, J. C., Ahn, I. E., Moreno, C., O'Brien, S. M., Jones, D. M., Cheung, L. W. K., Chong, E. Y., Kwei, K. A., et al. (2023) · doi:10.1158/1078-0432.c.6740549
Self-citationZhou, Z., Dai, L. M. J., Sha, Y., Qiu, T., Qin, S., Miao, Y., Xia, Y., Wu, W., Tang, H., Xu, W., et al. (2023) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2023.11.006
Joseph, R. E., Wales, T. E., Jayne, S., Britton, R. G., Fulton, D. B., Engen, J. R., Dyer, M. J. S., & Andreotti, A. H. (2024) · eLife · doi:10.7554/elife.95488.2
Chimeric Antigen Receptor-T Cells in the Modern Era of Chronic Lymphocytic Leukemia Treatment
Hatashima, A., Shadman, M. S., & Raghunathan, V. M. (2025) · Cancers · doi:10.3390/cancers17020268
Veyhe, S. R., Hansen, M. H., Cédile, O., Møller, M. B., Nielsen, M. K., Thomassen, M., Juul‐Jensen, K., Frederiksen, H., Dybkær, K., & Nyvold, C. G. (2025) · European Journal Of Haematology · doi:10.1111/ejh.14397
Khan, A. A., Ali, S. S., Zahid, M., Alshabrmi, F. M., Al‐Zoubi, R. M., Shkoor, M., Mohammmad, A., Wei, D., & Agouni, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-24745-7
Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center
Lin, K., Huynh, L. Y., Yang, X., Zanardo, E., Liborski, D., McDonough, M. M., Farooqui, M. Z. H., Nigris, E. D., Gandra, S. R., Duh, M. S., et al. (2025) · Advances in Hematology · doi:10.1155/ah/7492594
Chen, T. L., Harrington, B. K., Truxall, J., Wasmuth, R., Prouty, A., Sloan, S. L., Lehman, A. M., Sampath, D., Orlemans, E. O. M., Baiocchi, R. A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14111357
Self-citationChen, T. L., Harrington, B. K., Truxall, J., Wasmuth, R., Prouty, A., Sloan, S. L., Lehman, A. M., Sampath, D., Orlemans, E. O. M., Baiocchi, R. A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14111354
Self-citationHussain, S., Agarwal, M., Rajkhowa, S., Das, A., Sinha, S., & Zaki, M. E. A. (2026) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2026.2642911
Quaglia, F. M., Mannelli, L., Pagliaro, L., Scapinello, G., Schiattone, L., Farina, M., Novo, M., Angelillo, P., Sciarra, R., Maiolo, E., et al. (2026) · Hematological Oncology · doi:10.1002/hon.70190
Molecular characterization and functional analysis of poor-prognosis B-cell leukemias
Bougacha, N. (2019) · theses.fr (ABES) · doi:10.70675/86f73dd3z982dz4a64z9670zd4291a5714a3
Gargiulo, E. (2021) · theses.fr (ABES) · doi:10.70675/6478ae68zac8bz4d6dz994cz48cf61b11fc3
Andreescu, M., Tudorache, S. I., Moldovan, C., Moldovan, A.-D., Cochior, D., Popov, V., Andreescu, B., Ionescu, D., & Padurariu-Covit, M.-D. (2026) · Cancers · doi:10.3390/cancers18101621
Yan, Y., Wang, W. J., Yan, X., Xu, H. J., Wu, D., Wang, T. B., Liu, W. T., Huang, W. Y., An, G., Zou, D., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1739102
Santoleri, F., Pennese, E., Sanna, A., Mario, P., Lorenzo, T., Federica, D. B., Scortechini, I., Sabrina, G., Ranucci, E., Schiattone, L., et al. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70292
Mendez, M. T., Sanyal, T., Mamidi, M. K., Fernandes, S. M., Vesely, S. K., Mráz, M., Brown, J. R., Chakrabarty, J. L. H., & Ghosh, A. K. (2026) · Leukemia · doi:10.1038/s41375-026-03147-2
Clinical characteristics and outcome of a cohort of CLL patients with BTK T474 gatekeeper mutation
Omer, Z., Rogers, K. A., Yano, M., Rai, J., Chen, J., Woyach, J. A., Bhat, S. A., Jones, D., Grever, M. R., Hertlein, E. K., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025019251
Self-citationPROTAC degraders for lymphoid malignancies — current status and future directions
Wolska, A., & Robak, T. (2026) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2026.2755072
BindingDB Entry 50018558: Targeting Gatekeeper Mutations for Kinase Drug Discovery.
BindingDB (2024) · UC San Diego · doi:10.7270/q25t3qqp
BindingDB (2020) · UC San Diego · doi:10.7270/q2j96914
BindingDB Entry 50022614: Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
BindingDB (2025) · UC San Diego · doi:10.7270/q2qr52w3
BindingDB (2026) · UC San Diego · doi:10.7270/q23201sz
Metadata
- Authors
- Maddocks, K. J., Ruppert, A. S., Lozanski, G., Heerema, N. A., Zhao, W., Abruzzo, L., Lozanski, A., Davis, M., Gordon, A., Smith, L. L., Mantel, R., Jones, J. A., Flynn, J. M., Jaglowski, S. M., Andritsos, L. A., Awan, F., Blum, K. A., Grever, M. R., Johnson, A. J., Byrd, J. C., & Woyach, J. A.
- Affiliations
- The Ohio State University (US)
- Corresponding author
- Woyach, Jennifer A.
- ORCID
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2015-04-01
- Volume
- 1
- Issue
- 1
- Pages
- 80
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC4520535
- OpenAlex
- W1999128869
- Cited by
- 584
- References
- 21
- Citations by year
- 2026: 13 · 2025: 29 · 2024: 35 · 2023: 38 · 2022: 47 · 2021: 59 · 2020: 65 · 2019: 72 · 2018: 60 · 2017: 85 · 2016: 64 · 2015: 16
- FWCI
- 41.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (4p01ca081534-16)
- National Cancer Institute (P01CA095426, U10CA180861, P50CA140158, R01CA183444, P01CA95426, K23CA178183, R01CA177292, P01-CA-081534)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- chronic lymphocytic leukemia, BTK inhibitors, treatment discontinuation, Richter transformation, BTK mutations, PLCG2 mutations, relapse, deep sequencing, prognostic factors, sequential clinical trials, targeted therapy resistance
- MeSH terms
- Agammaglobulinaemia Tyrosine Kinase, Adenine, Adult, Aged, Aged, 80 and over, Clinical Trials as Topic, DNA Mutational Analysis, Female, Humans, Male, Middle Aged, Mutation, Ohio, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Recurrence, Risk Factors, Time Factors, Biomarkers, Tumor, Leukemia, Lymphocytic, Chronic, B-Cell, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Phospholipase C gamma, Kaplan-Meier Estimate, Molecular Targeted Therapy, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
